THIOTHIXENE HYDROCHLORIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for THIOTHIXENE HYDROCHLORIDE (THIOTHIXENE HYDROCHLORIDE).
Thiothixene hydrochloride is a typical antipsychotic that blocks postsynaptic dopamine D2 receptors in the central nervous system (CNS), particularly in the mesolimbic and mesocortical pathways. It also has alpha-adrenergic blocking activity and weak anticholinergic effects.
| Metabolism | Primarily metabolized by the liver via sulfoxidation, N-demethylation, and hydroxylation; involves cytochrome P450 enzymes, likely CYP1A2 and CYP3A4. |
| Excretion | Renal: primarily as metabolites, <1% unchanged; fecal: minor; biliary: some metabolites excreted in bile. |
| Half-life | Terminal elimination half-life: 34 hours (range 25–50 hrs) in adults; clinical context: allows once-daily dosing. |
| Protein binding | ~90% bound to albumin and alpha1-acid glycoprotein. |
| Volume of Distribution | Vd: 10–20 L/kg; indicates extensive tissue distribution. |
| Bioavailability | Oral: ~50% due to first-pass metabolism; IM: 100%. |
| Onset of Action | Oral: 30–60 minutes for antipsychotic effect; IM: 20–30 minutes. |
| Duration of Action | Oral: 12–24 hours; IM: up to 24 hours; clinical notes: duration may be longer with chronic use. |
| Molecular Weight | 400.45 |
Initial: 2-5 mg orally 3 times daily; maintenance: 15-30 mg orally per day in divided doses; maximum: 60 mg orally per day.
| Dosage form | CONCENTRATE |
| Renal impairment | No specific dose adjustment recommended; monitor for increased adverse effects with severe renal impairment. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 25-50%; Child-Pugh Class C: reduce dose by 50-75%. |
| Pediatric use | Children >12 years: initial 2 mg orally 3 times daily; maintenance 15-30 mg/day in divided doses; maximum 60 mg/day. For children <12 years: not recommended. |
| Geriatric use | Initial dose: 1-2 mg orally 1-2 times daily; increase slowly; maximum 15 mg/day due to increased sensitivity and risk of adverse effects. |
| 1st trimester | Limited human data; animal studies show teratogenicity at high doses. Use only if benefit outweighs risk. Avoid in first trimester if possible. |
| 2nd trimester | May cause extrapyramidal symptoms and withdrawal in neonates. Use with caution; monitor for maternal hypotension and fetal effects. |
| 3rd trimester | Risk of neonatal extrapyramidal symptoms, withdrawal, and respiratory depression. Avoid use near term unless essential. |
Clinical note
Comprehensive clinical and safety monograph for THIOTHIXENE HYDROCHLORIDE (THIOTHIXENE HYDROCHLORIDE).
| Placental transfer | Thiothixene crosses the placenta; fetal serum levels may approach maternal levels. Limited data on degree. |
| Breastfeeding | Thiothixene is excreted into breast milk in small amounts. Monitor infant for drowsiness, irritability, and developmental milestones. Avoid breastfeeding if infant has preexisting neurological conditions. |
■ FDA Black Box Warning
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Thiothixene is not approved for the treatment of dementia-related psychosis.
| Serious Effects |
Comatose statesCNS depression from alcohol or other drugsKnown hypersensitivity to thiothixene or pipotiazineBlood dyscrasiasSevere hepatic impairment
| Precautions | Neuroleptic malignant syndrome (NMS), Tardive dyskinesia, QT interval prolongation and risk of arrhythmias, Orthostatic hypotension, Seizure threshold lowering, Leukopenia/neutropenia/agranulocytosis |
| Food/Dietary | Avoid alcohol and grapefruit juice. Thiothixene may increase appetite; monitor weight. No significant food restrictions beyond general healthy diet. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Thiothixene is a typical antipsychotic (thioxanthene class). Data in pregnant women are limited. In animal studies, thiothixene has shown embryotoxicity and maternal toxicity at high doses. First trimester: Risk cannot be excluded; there is potential for congenital malformations, but absolute risk is low. Use only if benefit outweighs risk. Second and third trimesters: Exposure may increase risk for extrapyramidal symptoms (EPS) and/or withdrawal symptoms in neonates, including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding disorder. Neonates should be monitored. |
| Fetal Monitoring | During pregnancy: Monitor maternal blood pressure (especially for orthostatic hypotension), weight gain, blood glucose, and complete blood count. Assess for signs of EPS or tardive dyskinesia. Fetal monitoring: Serial fetal growth ultrasound (third trimester) and fetal heart rate monitoring (nonstress test) if clinically indicated (e.g., maternal complications). Neonate: Monitor for EPS, withdrawal symptoms (especially if third trimester exposure), and neurobehavioral adaptation after delivery. |
| Fertility Effects | Thiothixene, like other typical antipsychotics, can elevate serum prolactin levels via dopamine D2 receptor blockade in the pituitary. Hyperprolactinemia may suppress the hypothalamic-pituitary-gonadal axis, leading to menstrual irregularities, anovulation, and reduced fertility in females. In males, it may cause decreased libido, erectile dysfunction, or oligospermia. These effects are generally reversible upon dose reduction or discontinuation. |
| Clinical Pearls | Thiothixene is a typical antipsychotic with high potency at D2 receptors. Monitor for extrapyramidal symptoms (EPS), especially acute dystonia and akathisia. Use low starting doses in elderly patients. QT prolongation risk; obtain baseline ECG and monitor electrolytes. Avoid concurrent use with other CNS depressants. |
| Patient Advice | Take exactly as prescribed; do not stop suddenly without consulting your doctor. · Avoid alcohol and other CNS depressants. · Rise slowly from sitting or lying to prevent dizziness. · Report any muscle stiffness, tremors, restlessness, or unusual movements. · May cause drowsiness; use caution when driving or operating machinery. · Avoid overheating; monitor for increased body temperature. · Notify your doctor if you experience irregular heartbeat, fainting, or seizures. |